Peng Yong, Yang Xiaojuan, Zhang Yizheng
College of Life Sciences, Sichuan University, Chengdu, PR China.
Appl Microbiol Biotechnol. 2005 Nov;69(2):126-32. doi: 10.1007/s00253-005-0159-7. Epub 2005 Nov 12.
Accumulation of fibrin in the blood vessels usually results in thrombosis, leading to myocardial infarction and other cardiovascular diseases. For thrombolytic therapy, microbial fibrinolytic enzymes have now attracted much more attention than typical thrombolytic agents because of the expensive prices and the undesirable side effects of the latter. The fibrinolytic enzymes were successively discovered from different microorganisms, the most important among which is the genus Bacillus from traditional fermented foods. The physiochemical properties of these enzymes have been characterized, and their effectiveness in thrombolysis in vivo has been further identified. Therefore, microbial fibrinolytic enzymes, especially those from food-grade microorganisms, have the potential to be developed as functional food additives and drugs to prevent or cure thrombosis and other related diseases.
血管中纤维蛋白的积累通常会导致血栓形成，进而引发心肌梗死和其他心血管疾病。对于溶栓治疗而言，由于典型溶栓剂价格昂贵且存在不良副作用，微生物纤溶酶如今比它们更受关注。纤溶酶先后从不同微生物中被发现，其中最重要的是来自传统发酵食品中的芽孢杆菌属。这些酶的理化性质已得到表征，其体内溶栓效果也已得到进一步确认。因此，微生物纤溶酶，尤其是来自食品级微生物的纤溶酶，有潜力被开发成为功能性食品添加剂和药物，用于预防或治疗血栓形成及其他相关疾病。
